<DOC>
	<DOC>NCT01027208</DOC>
	<brief_summary>To provide extended access to Ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous Phase II study (CA163-107)</brief_summary>
	<brief_title>A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Women aged 20 years or older Patients with metastatic breast cancer whose primary lesion was definitely diagnosed to be breast by histological or cellular examination Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of â‰¥2</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>